A minimally invasive approach to thymectomy may be a more effective approach for thymus gland removal in patients with myasthenia gravis (MG). Findings from a small study, detailed in Journal of Cardiothoracic Surgery, showed that compared with transsternal thymectomy, thoracoscopic […]
Small Study Shows Benefit With Minimally Invasive Thymectomy in MG Read More »
Treatment with Janus kinase (JAK) inhibitors has the potential to fill an unmet need for patients with concurrent myeloid disorders and adult-onset inflammatory syndromes, according to new research published in Leukemia Research.1 In recent years, it’s been estimated that 10%
JAK Inhibitors Show Promise in Concurrent Myeloid Disorders, IADs Read More »
The subcutaneous (SC) formulation of efgartigimod is noninferior to the intravenous (IV) formulation of the treatment for generalized myasthenia gravis (gMG), showed late-stage trial findings.1 Publishing new data in Neurotherapeutics, researchers have detailed complete findings from the phase 3 ADAPT-SC
SC Efgartigimod Shows Noninferiority to IV Formulation in gMG Read More »
